TRIAL OVERVIEW

TRIAL DESIGN

ANZUPGO was evaluated in DELTA 1 & DELTA 2: two randomized, multicenter, double-blind, vehicle controlled, 16-week trials. Upon completion, patients were eligible to enter a single-arm, 36-week open-label extension, DELTA 3.^1,3

KEY INCLUSION CRITERIA⁴:

Inadequate response to or inadvisable use of topical corticosteroids (TCS)

RANDOMIZED, MULTICENTER, DOUBLE-BLIND, VEHICLE-CONTROLLED TRIALS

Primary endpoint¹:

IGA-CHE treatment success (IGA-CHE 0/1 with at least a 2-point improvement from baseline) at Week 16

Select inclusion criteria⁴:

CHE >3 months or relapsed ≥2x within a year
IGA-CHE score of 3 (moderate) or 4 (severe)
HESD-itch score ≥4
Inadequate response to TCS within 12 months or TCS medically inadvisable

SINGLE-ARM, OPEN-LABEL
EXTENSION TRIAL

Objective¹:

To evaluate the long-term safety of ANZUPGO when used as needed

Select inclusion criteria⁵:

Participants must have met the eligibility criteria at screening and baseline and have completed the treatment period in DELTA 1 and 2

BID=twice daily; HESD=Hand Eczema Symptom Diary; IGA-CHE=Investigator's Global Assessment of Chronic Hand Eczema.

What is IGA-CHE?

The IGA–CHE is a clinician-reported outcome that uses the following criteria to score and assess CHE disease severity.^1,6

Clear 0

No signs of erythema, scaling, hyperkeratosis/ lichenification, vesiculation, edema, or fissures

Almost Clear 1

Barely perceptible erythema and no signs of scaling, hyperkeratosis/ lichenification, vesiculation, edema, or fissures

Mild 2

At least 1: slight but definite erythema, slight but definite scaling, slight but definite hyperkeratosis/ lichenification

At least 1: scattered vesicles without erosion, barely palpable edema, superficial fissures

Moderate 3

At least 1: clearly perceptible erythema, clearly perceptible scaling, clearly perceptible hyperkeratosis/ lichenification

At least 1: clustered vesicles without visible erosion, definite edema, definite fissures

Severe 4

At least 1: marked erythema, marked and thick scaling, marked hyperkeratosis/ lichenification

At least 1: high density of vesicles with erosions, marked edema, one or more deep fissures

BASELINE DEMOGRAPHICS^1†

^†Pooled data from DELTA 1 and DELTA 2 trials.

PRIMARY SUBTYPE DISTRIBUTION^1,7,8‡

^‡Only one case of contact urticaria/protein contact dermatitis was reported in the cream vehicle group; none in the ANZUPGO group.^1,9

Before & After Images

See the difference that ANZUPGO
made in the hands of these patients

Rapid, Powerful Efficacy

See results from the rigorous
16-week studies

GO efficacy

Rigorously evaluated in the
largest clinical trials to date for
adult patients with moderate-
to-severe CHE^1,3

TRIAL DESIGN

KEY INCLUSION CRITERIA⁴:

RANDOMIZED, MULTICENTER, DOUBLE-BLIND, VEHICLE-CONTROLLED TRIALS

SINGLE-ARM, OPEN-LABEL
EXTENSION TRIAL

TREATMENT SUCCESS
FOR IGA-CHE

TREATMENT SUCCESS FOR IGA-CHE

BASELINE DEMOGRAPHICS^1†

PRIMARY SUBTYPE DISTRIBUTION^1,7,8‡

Before & After Images

Rapid, Powerful Efficacy

INDICATION

IMPORTANT SAFETY INFORMATION AND INDICATION

IMPORTANT SAFETY INFORMATION

REFERENCES:

You are about to leave ANZUPGOHCP.com

Rigorously evaluated in the largest clinical trials to date for adult patients with moderate-to-severe CHE1,3

TRIAL DESIGN

KEY INCLUSION CRITERIA4:

RANDOMIZED, MULTICENTER, DOUBLE-BLIND, VEHICLE-CONTROLLED TRIALS

SINGLE-ARM, OPEN-LABEL EXTENSION TRIAL

TREATMENT SUCCESS FOR IGA-CHE

TREATMENT SUCCESS FOR IGA-CHE

BASELINE DEMOGRAPHICS1†

PRIMARY SUBTYPE DISTRIBUTION1,7,8‡

Before & After Images

Rapid, Powerful Efficacy

INDICATION

IMPORTANT SAFETY INFORMATION AND INDICATION

IMPORTANT SAFETY INFORMATION

REFERENCES:

Rigorously evaluated in the
largest clinical trials to date for
adult patients with moderate-
to-severe CHE^1,3

KEY INCLUSION CRITERIA⁴:

SINGLE-ARM, OPEN-LABEL
EXTENSION TRIAL

TREATMENT SUCCESS
FOR IGA-CHE

BASELINE DEMOGRAPHICS^1†

PRIMARY SUBTYPE DISTRIBUTION^1,7,8‡